Coagulation and non-coagulation effects of thrombin

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 10, 2016, Pages 1908-1916

  Posma, J J N ^a   Posthuma, J J ^a   Spronk, H M H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

atherosclerosis; blood coagulation; cardiovascular diseases; protease activated receptors; thrombin

Indexed keywords

APC PROTEIN; BLOOD CLOTTING FACTOR 8; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRIN; FIBRINOGEN; GUANINE NUCLEOTIDE BINDING PROTEIN; HETERODIMER; HOMODIMER; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; SERINE PROTEINASE; THROMBIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL PROTECTION; CONCENTRATION (PARAMETERS); ENZYME ACTIVATION; ENZYME INHIBITION; FEEDBACK SYSTEM; INTRACELLULAR SIGNALING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; THROMBOCYTE; TRANSACTIVATION; ANIMAL; BLOOD; CYTOLOGY; DRUG EFFECTS; HEMOSTASIS; HUMAN; INFLAMMATION; METABOLISM; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; TRANSCRIPTION INITIATION;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HEMOSTASIS; HUMANS; INFLAMMATION; PLATELET ACTIVATION; PROTEIN MULTIMERIZATION; RECEPTORS, PROTEINASE-ACTIVATED; RECEPTORS, THROMBIN; SERINE ENDOPEPTIDASES; SERINE PROTEASES; SIGNAL TRANSDUCTION; THROMBIN; TRANSCRIPTIONAL ACTIVATION;

EID: 84994444384     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13441     Document Type: Review

References (85)

1. Bae J-S, Kim I-S, Rezaie AR. Thrombin down-regulates the TGF-β-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1. J Cell Physiol 2010; 225: 233–9.
2. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93: 327–58.
3. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023–7.
4. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009; 459: 356–63.
5. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S. Action of molecular switches in GPCRs – theoretical and experimental studies. CMC 2012; 19: 1090–109.
6. Flock T, Ravarani CNJ, Sun D, Venkatakrishnan AJ, Kayikci M, Tate CG, Veprintsev DB, Babu MM. Universal allosteric mechanism for Gα activation by GPCRs. Nature 2015; 524: 173–9.
7. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579–621.
8. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255–60.
9. Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs) – focus on receptor–receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal 2013; 11: 86–112.
10. van den Biggelaar M, Hernández-Fernaud JR, van den Eshof BL, Neilson LJ, Meijer AB, Mertens K, Zanivan S. Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Blood 2014; 123: e22–36.
11. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258–64.
12. Stefanini L, Boulaftali Y, Ouellette TD, Holinstat M, Desire L, Leblond B, Andre P, Conley PB, Bergmeier W. Rap1–Rac1 circuits potentiate platelet activation. Arterioscler Thromb Vasc Biol 2012; 32: 434–41.
13. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nürnberg B. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995; 269: 690–3.
14. Abraham LA, Macfarlane SR, Seatter MJ, Mackie EJ, Kanke T, Hunter GD, Plevin R. Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1. J Bone Miner Res 1999; 14: 1320–9.
15. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745–54.
16. Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front Endocrinol 2014; 5: 943–59.
17. Offermanns S, Mancino V, Revel JP, Simon MI. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 1997; 275: 533–6.
18. Donovan FM, Pike CJ, Cotman CW, Cunningham DD. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J Neurosci 1997; 17: 5316–26.
19. Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular biology. Vascul Pharmacol 2014; 62: 72–81.
20. Nieman MT. Protease-activated receptor 4 uses anionic residues to interact with α-thrombin in the absence or presence of protease-activated receptor 1. Biochemistry 2008; 47: 13279–86.
21. Arachiche A, Mumaw MM, la Fuente de M, Nieman MT. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by thrombin. J Biol Chem 2013; 288: 32553–62.
22. Lin H, Liu AP, Smith TH, Trejo J. Cofactoring and dimerization of proteinase-activated receptors. Pharmacol Rev 2013; 65: 1198–213.
23. Danckwardt S, Hentze MW, Kulozik AE. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med 2013; 91: 1257–71.
24. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106: 2605–12.
25. Hung DT, Vu TH, Nelken NA, Coughlin SR. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol 1992; 116: 827–32.
26. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178–84.
27. Bae JS, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104: 2867–72.
28. Bae J-S, Vaughan PJ, Kim Y-U, Pike CJ, Cotman CW, Park M-K, Rezaie AR, Cunningham DD. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J Cell Physiol 2009; 219: 744–51.
29. Donovan FM, Cunningham DD. Signaling pathways involved in thrombin-induced cell protection. J Biol Chem 1998; 273: 12746–52.
30. McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA 2007; 104: 5662–7.
31. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070–7.
32. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005; 26: 1–43.
33. 2+-dependent signaling pathways. J Biol Chem 2009; 284: 20638–48.
34. Madhusudhan T, Wang H, Straub BK, Gröne E, Zhou Q, Shahzad K, Müller-Krebs S, Schwenger V, Gerlitz B, Grinnell BW. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 2012; 119: 874–83.
35. Pavic G, Grandoch M, Dangwal S, Jobi K, Rauch BH, Doller A, Oberhuber A, Akhyari P, Schrör K, Fischer JW. Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. Circulation 2014; 130: 1700–11.
36. Yu G, Jiang P, Xiang Y, Zhang Y, Zhu Z, Zhang C, Lee S, Lee W, Zhang Y. Increased expression of protease-activated receptor 4 and trefoil factor 2 in human colorectal cancer. PLoS ONE 2015; 10: e0122678.
37. Gomides LF, Lima OCO, Matos NA, Freitas KM, Francischi JN, Tavares JC, Klein A. Blockade of proteinase-activated receptor 4 inhibits neutrophil recruitment in experimental inflammation in mice. Inflamm Res 2014; 63: 935–41.
38. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000; 275: 13502–9.
39. Blackhart BD, Emilsson K, Nguyen D, Teng W, Martelli AJ, Nystedt S, Sundelin J, Scarborough RM. Ligand cross-reactivity within the protease-activated receptor family. J Biol Chem 1996; 271: 16466–71.
40. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A. ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007; 8: 1303–12.
41. Lidington EA, Steinberg R, Kinderlerer AR, Landis RC, Ohba M, Samarel A, Haskard DO, Mason JC. A role for proteinase-activated receptor 2 and PKC in thrombin-mediated induction of decay-accelerating factor on human endothelial cells. Am J Physiol Cell Physiol 2005; 289: C1437–47.
42. Sevigny LM, Austin KM, Zhang P, Kasuda S, Koukos G, Sharifi S, Covic L, Kuliopulos A. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler Thromb Vasc Biol 2011; 31: e100–6.
43. Komarova YA, Mehta D, Malik AB. Dual regulation of endothelial junctional permeability. Sci STKE; 2007; 2007: re8.
44. Chen CH, Paing MM, Trejo J. Termination of protease-activated receptor-1 signaling by arrestins is independent of receptor phosphorylation. J Biol Chem 2004; 279: 10020–31.
45. Paing MM, Stutts AB, Kohout TA, Lefkowitz RJ, Trejo J. Arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation. J Biol Chem 2002; 277: 1292–300.
46. Stalheim L, Ding Y, Gullapalli A, Paing MM, Wolfe BL, Morris DR, Trejo J. Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking. Mol Pharmacol 2005; 67: 78–87.
47. DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000; 148: 1267–81.
48. Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood 2014; 124: 1553–62.
49. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110: 3909–16.
50. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 2015; 125: 2898–907.
51. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H, Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2787–92.
52. Rezaie AR. The occupancy of endothelial protein C receptor by its ligand modulates the PAR-1 dependent signaling specificity of coagulation proteases. IUBMB Life 2011; 63: 390–6.
53. Soh UJK, Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol 2010; 160: 191–203.
54. Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ, Luttrell LM. β-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem 2002; 277: 9429–36.
55. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, Caron MG, Lefkowitz RJ, Luttrell LM. The stability of the G protein-coupled receptor–β-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 2003; 278: 6258–67.
56. DeFea K. β-Arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 2009; 153: S298–309.
57. Shenoy SK, Barak LS, Xiao K, Ahn S, Berthouze M, Shukla AK, Luttrell LM, Lefkowitz RJ. Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation. J Biol Chem 2007; 282: 29549–62.
58. Shenoy SK, Lefkowitz RJ. Angiotensin II-stimulated signaling through G proteins and beta-arrestin. Sci STKE 2005; 2005: cm14.
59. Huang J, Sun Y, Huang XY. Distinct roles for Src tyrosine kinase in 2-adrenergic receptor signaling to MAPK and in receptor internalization. J Biol Chem 2004; 279: 21637–42.
60. Sun Y, Huang J, Xiang Y, Bastepe M, Jüppner H, Kobilka BK, Zhang JJ, Huang X-Y. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 2006; 26: 53–64.
61. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261–73.
62. Wang P, DeFea KA. Protease-activated receptor-2 simultaneously directs β-arrestin-1-dependent inhibition and Gαq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 2006; 45: 9374–85.
63. Wang P, Kumar P, Wang C, DeFea KA. Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins. Biochem J 2007; 408: 221–30.
64. Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem 2007; 282: 20634–46.
65. Steen A, Larsen O, Thiele S, Rosenkilde MM. Biased and G protein-independent signaling of chemokine receptors. Front Immunol 2014; 5: 277–90.
66. Borissoff JI, Schwartz RS, ten Cate H, Spronk HMH. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746–60.
67. Stoop AA, Lupu F, Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall a potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol 2000; 20: 1143–9.
68. Borissoff JI, Heeneman S, Kilinç E, Kassák P, van Oerle R, Winckers K, Govers-Riemslag JWP, Hamulyák K, Hackeng TM, Daemen MJAP, ten Cate H, Spronk HMH. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821–30.
69. Wei HJ, Li YH, Shi GY, Liu SL, Chang PC, Kuo CH, Wu HL. Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation. Cardiovasc Res 2011; 92: 317–27.
70. Borissoff JI, Otten JJT, Heeneman S, Leenders P, van Oerle R, Soehnlein O, Loubele STBG, Hamulyák K, Hackeng TM, Daemen MJAP, Degen JL, Weiler H, Esmon CT, van Ryn J, Biessen EAL, Spronk HMH, ten Cate H. Genetic and pharmacological modifications of thrombin formation in apolipoprotein E-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS ONE 2013; 8: e55784.
71. Preusch MR, Ieronimakis N, Wijelath ES, Ricks J, Cabbage S, Bea F, Reyes M, van Ryn J, Rosenfeld ME. Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug Des Dev Ther 2015; 9: 5203–11.
72. Pingel S, Tiyerili V, Mueller J, Werner N, Nickenig G, Mueller C. Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch Med Sci 2014; 1: 154–60.
73. Liu X, Ni M, Ma L, Yang J, Wang L, Liu F, Dong M, Yang X, Zhang M, Lu H, Wang J, Zhang C, Jiang F, Zhang Y. Targeting blood thrombogenicity precipitates atherothrombotic events in a mouse model of plaque destabilization. Sci Rep 2015; 5: 10225.
74. Loubele STBG, ten Cate H, Spronk HMH. Anticoagulant therapy in critical organ ischaemia/reperfusion injury. Thromb Haemost 2010; 104: 136–42.
75. Loubele STBG, Spek CA, Leenders P, van Oerle R, Aberson HL, van der Voort D, Hamulyák K, Petersen LC, Spronk HMH, ten Cate H. Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. J Thromb Haemost 2009; 7: 290–8.
76. Ringwala SM, Dibattiste PM, Schneider DJ. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis 2012; 34: 291–6.
77. Napoli C, Cicala C, Wallace JL, de Nigris F, Santagada V, Caliendo G, Franconi F, Ignarro LJ, Cirino G. Protease-activated receptor-2 modulates myocardial ischemia–reperfusion injury in the rat heart. Proc Natl Acad Sci USA 2000; 97: 3678–83.
78. De Jong AM, Maass AH, Oberdorf-Maass SU, van Veldhuisen DJ, van Gilst WH, van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res 2011; 89: 754–65.
79. Harada M, van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495–502.
80. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954–68.
81. de Ridder GG, Lundblad RL, Pizzo SV. Actions of thrombin in the interstitium. J Thromb Haemost 2015; 14: 40–47.
82. Borensztajn K, Bresser P, van der Loos C, Bot I, van den Blink B, den Bakker MA, Daalhuisen J, Groot AP, Peppelenbosch MP, von der Thüsen JH, Spek CA. Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury. Am J Pathol 2010; 177: 2753–64.
83. 2+ in cardiomyocytes and proliferation of cardiac fibroblasts from chick embryos. Bull Exp Biol Med 2007; 144: 760–3.
84. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 2007; 116: 2298–306.
85. Schuepbach RA, Madon J, Ender M, Galli P, Riewald M. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost 2012; 10: 1675–84.